Ponatinib (AP24534) inhibits MEKK3-KLF signaling and prevents formation and progression of cerebral cavernous malformations

	Ponatinib (AP24534) inhibits MEKK3-KLF signaling and prevents formation and progression of cerebral cavernous malformations
发表期刊	SCIENCE ADVANCES
	2018
卷号	4 期号:11 页码:文献号 eaau0731：1-11
	Jaesung P.Choi; Rui Wang; Xi Yang; Xian Wang; Lu Wang; Ka Ka Ting; Matthew Foley; Victoria Cogger; Zhuo Yang; Liu F(刘峰); Han ZM(韩之明); Renjing Liu; Jonathan Baell; Xiangjian Zheng
文献类型	期刊论文
条目标识符	http://ir.ioz.ac.cn/handle/000000/13477
专题	干细胞与生殖生物学国家重点实验室
推荐引用方式 GB/T 7714	Jaesung P.Choi,Rui Wang,Xi Yang,et al. Ponatinib (AP24534) inhibits MEKK3-KLF signaling and prevents formation and progression of cerebral cavernous malformations[J]. SCIENCE ADVANCES,2018,4(11):文献号 eaau0731：1-11.
APA	Jaesung P.Choi.,Rui Wang.,Xi Yang.,Xian Wang.,Lu Wang.,...&Xiangjian Zheng.(2018).Ponatinib (AP24534) inhibits MEKK3-KLF signaling and prevents formation and progression of cerebral cavernous malformations.SCIENCE ADVANCES,4(11),文献号 eaau0731：1-11.
MLA	Jaesung P.Choi,et al."Ponatinib (AP24534) inhibits MEKK3-KLF signaling and prevents formation and progression of cerebral cavernous malformations".SCIENCE ADVANCES 4.11(2018):文献号 eaau0731：1-11.